Avastin fails to win FDA panel support

12/5/2007 | Wall Street Journal (free content), The · NYTimes.com

An FDA advisory panel voted 5-4 Wednesday against approving Genentech's cancer drug Avastin as a first-line treatment for patients with recurrent or metastatic breast cancer. A National Cancer Institute study showed no significant difference in overall survival for patients who took Avastin with Taxol compared to those taking Taxol alone.

View Full Article in:

Wall Street Journal (free content), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ